Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Oct 25, 2021 12:42pm
140 Views
Post# 34045633

RE:RE:RE:2021 Insider Buying

RE:RE:RE:2021 Insider BuyingIt's a mixture of cash and options granted for free. Prior to the annual meeting I had suggested the same to them. The Chairwomen's reponse was that the options align them with shareholders. In my book, unless you've paid for your ownership and put your own skin-in-the-game, it's a very mild form of alignment.  Management is different, but for Boards, it is often seen as free icing on the cake --I paid nothing and may get a windfall without risking one penny of my own. So I disageed with her and PL on that.  None of them are at the point in their careers where they are desperately in need of all the cash they are paid, if any. Many firms strongly urge their boards to use some of that to buy shares when allowed. Insider buying has been extremely disappointing given where the company says they are in moving the pipeline along. 

The conclusion from an outsider looking in at this quarters insider buying activity would be either management has been good at convincing gullible shareholders to stick with the oncology potential, or management/BOD just missed potentially one of the last chances to invest at this level and make some serious money for themselves. It sure would have looked a whole lot better had insiders jumped in when they could have.  I don't go for them needing to worry about taxes and being cash strapped and all that junk.  We are too and so is anyone else buying shares. Insider buying shows belief in the positive elements of the strategy your management is telling everyone publicly. When little or no buying occurs prior to a potentially significant event, it shows a real lack of confidence from "insiders".  Not at all a good look in my opinion. 

Scioto1 wrote:
Does the company have the option to compensate board appointments with with stock and not cash?? When I looked at the the annual report looks like they make pretty good coin to serve on this board. Maybe there would be more incentive if it was paid in stock. Please advise.


<< Previous
Bullboard Posts
Next >>